In this randomized controlled trial, inebilizumab, an anti-CD19 monoclonal antibody, reduced the risk of flares and increased ...

New diagnostic criteria are enhancing accuracy in identifying IgG4-related periaortitis, periarteritis, and retroperitoneal ...

Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...

The FDA has approved Uplizna (inebilizumab-cdon) for the treatment of immunoglobulin G4-related disease in adult patients.

Uplizna is the first approved treatment for immunoglobulin G4-related disease (IgG4-RD), a chronic inflammatory condition ...

Leerink analysts noted, however, that Uplizna’s slow onset of therapeutic efficacy compares unfavorably to would-be ...

Dr. Laken brings over 25 years of leadership experience in research, development operations, scientific assessment and ...

The FDA on Thursday gave the green light to Uplizna in IgG4-related disease, making it the first and only approved treatment for the rare and recently recognized autoimmune condition, according to ...

It was a busy week for the biotech sector, with lots of regulatory and pipeline updates amid fears of a global recession ...

Compass Therapeutics (NASDAQ:CMPX – Get Free Report) had its price objective upped by equities researchers at HC Wainwright from $10.00 to $24.00 in a research report issued on Friday,Benzinga reports ...

Three doses of COVID-19 mRNA vaccination induce long-lasting antibody and memory B-cell responses, according to a study of ...